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SUMMARY
The circumoval precipitin test (COPT), enzyme-linked immunosorbent assay (ELISA) and the immunoblotting anti-adult worm
antigen (AWA) and soluble egg antigen (SEA) tests were applied to 17 chronically schistosome-infected patients for the detection of
anti-Schistosoma mansoni antibodies before and on four occasions after oxamniquine administration over a period of six months.
Compared to a control group, schistosomiasis patients showed high levels of IgG antibodies in AWA and SEA-ELISA. A decrease in
IgG levels was observed six months after treatment, although negative reactions were not obtained. Significant decreases in IgG1,
IgG3 and, mainly, IgG4, but not anti-SEA IgG2 levels were observed six months after treatment, again without negativity. Analysis of
anti-AWA IgG antibodies by immunoblotting before treatment showed a 31 kDa strand in 14 patients (82%) which disappeared in
three cases up to six months after treatment; furthermore, anti-SEA IgG antibodies showed the same band in nine patients (53%)
before treatment, which disappeared in only four cases up to six months after treatment.
KEYWORDS: Schistosomiasis diagnosis; Schistosomiasis cure evaluation; Immunenzymatic tests; Immunoblotting.
INTRODUCTION
In Brazil there are at least 2,500,000 individuals infected with
Schistosoma mansoni and about 25 millions live in areas where the
transmission of this helminthiasis may be possible32. The laboratory
diagnosis of active schistosomiasis mansoni is made principally by the
finding of S. mansoni eggs in the stool9. However, fecal parasitologic
tests are not considered to have high sensitivity because of factors such
as irregularity in Schistosoma egg shedding3,8,  absence of egg laying
just after anti-schistosome treatment even if not successful and tissue
egg retaining due to intestinal fibrosis29. Thus, several immunological
tests using crude or purified egg and adult worm antigens have been
developed in the last decades to detect anti-S. mansoni antibodies and
some of them have been proposed for treatment evaluation.
The circumoval precipitin test (COPT) is one of the exams used for
the diagnosis of schistosomiasis and for the evaluation of anti-
schistosome treatment31 and consists of immune complex formation
around schistosome eggs incubated with serum from schistosome-
infected individuals. It is considered as a highly sensitive and specific
test and usually becomes non-reactive from 6 to 12 months after anti-
schistosome treatment14,33. However, in some instances, patients continue
to have positive COPT results after specific anti-schistosome treatment
or test negativity occurs only a long time after treatment16.
Immunoenzymatic tests for anti-S. mansoni antibodies utilize
antigens obtained from either adult worms or eggs. Some of these tests
show a decrease in anti-schistosome antibody levels soon after specific
treatment34, while others show the persistence of high antibody levels
up to 18 months10. When IgG subclasses are analyzed there is a decrease
in all subclasses, with special relevance in the case of IgG42.
Immunoblotting tests have been  used to detect AWA antibodies since
an immunogenic fraction with a molecular weight of 31-32 kDa (Sm
31/32) was considered to be the most frequently recognized fraction
and could therefore be used as a serologic marker35,36,43. Furthermore
this fraction became negative or decreased in the serum of treated patients
exposed to a low infection risk35,36. On the other hand, KIMURA22 did
not obtain the same results.
Using the immunoblotting test for SEA, NOYA et al.30 studied a
group of patients after therapy and identified a special fraction of about
31 kDa which decreased after specific treatment. This fraction,
corresponding to the Omega 1 antigen described by DUNNE et al.7, was
present in a special schistosome egg antigen known as cation exchanging
fraction-6 (CEF-6) and has been considered an important diagnostic
marker for cure control. Moreover, this antigen is one subcomponent of
COPT and has been considered as a very sensitive and specific
antigen5,27,28. DOENHOFF et al.4, employing this antigen as a serologic
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marker, observed 50% and 80% negative reactions in schistosomiasis
patients from Santa Lucia, West Indies, six and 12 months after treatment,
respectively. However, a similar evaluation of patients from Puerto Rico
did not show the same results6,15.
The occurrence of controversial results when the same immunological
technique is  used in different populations justifies the evaluation of
tests usually employed in the diagnosis and cure control of
schistosomiasis under our operational conditions in order to standardize
immunological evaluation of schistosomiasis treatment. Furthermore,
the decrease of the rate of infection with S. mansoni in Brazil, particularly
in São Paulo State, strengthens the importance of using an immunological
technique of diagnosis rather than parasitological tests in epidemiological
surveys.
MATERIAL AND METHODS
Patients and sera: After informed consent, 17 chronically
schistosome-infected male and female patients ranging in age from 17
to 77 years (mean age = 33), with either the intestinal or hepatointestinal
form of the disease were studied. All of them were migrants from different
Brazilian endemic areas for schistosomiasis, living in São Paulo City
and admitted to the Hospital das Clínicas, Universidade de São Paulo.
During the study they did not return to endemic areas. Blood and fecal
samples were taken immediately before and 40, 90, 150 and 180 days
after treatment with oxamniquine (15 mg/kg weight). Blood was allowed
to clot at room temperature and centrifuged and serum was separated
and kept frozen at –20 °C until testing. Diagnosis of schistosomiasis
mansoni before and after treatment was performed by the Kato-Katz
method21, with three microscope slides prepared for each sample. Control
sera were obtained from 30 Brazilian blood donor volunteers.
Adult worm antigen (AWA) preparation: Adult S. mansoni worms
(BH strain) were collected by portal perfusion of infected hamsters with
0.9% sodium chloride solution. Worms were thoroughly washed with
PBS and stored at –20 °C. Approximately 12,000 adult male and female
worms were thawed, homogenized in saline with 1 mM
phenylmetylsulfonyl fluoride (PMSF), disrupted by hand and
homogenized with a Potter-Elvehjem apparatus for 1 hour at 4 °C. They
were then centrifuged at 26,000 x g for 1 hour at 4 °C using an SW 41
rotor (L-8 ultracentrifuge, Beckman Instruments Inc, Palo Alto, CA,
USA).
Soluble egg antigen (SEA) preparation: S. mansoni eggs were
isolated from liver and intestinal walls of infected hamsters by differential
sieving and washed by repeated centrifugation. SEA was prepared as
described by BOROS & WARREN1.
The protein contents of AWA and SEA were determined by the
method of LOWRY et al.25 using bovine albumin as standard, lyophilized
in small aliquots and stored at –70 °C.
Circumoval precipitin test (COPT): This method was performed
as previously described by OLIVER-GONZÁLEZ31. S. mansoni eggs
obtained as above were adjusted to a concentration of 50 eggs/10 L in
hypertonic solution, added to 25 L of patient serum and incubated at
37 °C for 48 hours. The reaction was read under the light microscope
according to the criteria described by SPENCER et al. 40, i.e. < 10% of
eggs with circumoval precipitation  indicated in a negative reaction and
>/= 10% a positive reaction.
Enzyme-linked immunosorbent assay (ELISA): Polystyrene
microtiter plates (Costar, Cambridge, MA, USA) were coated with 50
L of either AWA or SEA at a protein concentration of 10 L/mL diluted
in PBS supplemented with 0.05 Tween 20 (PBS-T), kept for 2 hours at
37 °C and then for 16 hours at 4 °C. Between the steps of the reaction
wells were washed three times with 200 L of PBS-T for 1 hour at room
temperature. Then 50 L of diluted serum (1:200) were added to the
wells and incubated for 1 hour at 37 °C; after this time 50 L of
horseradish peroxidase goat anti-human IgG  (SIGMA, Chemical Co.,
St. Louis, MO, USA; IgG 1:5,000 for AWA and SEA) were added. After
incubation for 1 hour at 37 °C, 50 L of substrate solution were added
and 15 minutes after incubation at room temperature the enzymatic
reaction was stopped by the addition of 50 L of 4 N H2SO4. Absorbance
was read at 492 nm in a Titertek Multiskan MCC/340P, model 2.20
(Labsystems, Finland) and the results were obtained by duplicate
readings. Optimal dilutions of the antigen protein concentration for
coating the wells and serum and conjugate dilutions were determined
previously by checkerboard titration using pooled positive and negative
sera. An optical density (OD) greater than the mean plus two standard
deviations of  the value for 30 healthy Brazilian individuals was
considered to be the cut-off point.
ELISA for the anti-SEA IgG subclass: This test was performed
with sera obtained before and 180 days after anti-S. mansoni treatment.
IgG subclass antibodies were detected using a slightly different protocol:
50 L of serum samples were diluted 1:200 in PBS-Tg and incubated
for 16 hours at 37 °C. Mouse monoclonal antibodies specific for each
human IgG subclass (SIGMA Chemical Co.): anti-IgG1 (clone HP-6001),
anti-IgG2 (clone HP-6014), anti IgG3 (clone HP-6050) and IgG4 (clone
HP-6025) were used at 1:1,000  in blocking buffer. Thereafter, 50 L of
peroxidase-conjugated sheep anti-mouse Ig (SIGMA Chemical Co.) at
1:1,000 dilution in blocking buffer were added for 1 hour at 37 °C.
Subsequently the protocol was performed as previously described.
Immunoblotting: Proteins were separated electrophoretically under
reducing conditions by one-dimensional SDS-PAGE as described by
LAEMMLI24. AWA (215 g) and SEA (225 g) were boiled for 3 minutes
and applied to the 10% polyacrylamide gel using a Mini Protean II
apparatus (Bio-Rad Labs, Hercules, CA, USA). High range molecular
weight standards were also obtained from Bio-Rad Labs.
The separated proteins were electrotransferred to NCP using a Trans
Blot transfer cell apparatus (Bio-Rad Labs) and 4 mm strips were cut.
Non-specific sites were blocked with 0.05% Tween 20 supplemented
with 5% non-fat dry milk in PBS adjusted to pH 7.4 (PBS-Tm). Serum
diluted at 1:100 in PBS-Tg was added and kept for 1 hour at 37 °C.
After washing in PBS-T, the enzymatic conjugate labeled with alkaline
phosphatase for human anti-IgG at a previously determined optimal
dilution was added and incubated for 2 hours at 37 °C. Then, after another
washing, blots were visualized with the enzymatic substrate bromo-cloro-
indolyl-phosphate and nitroblue tetrazolium in 1 M Tris (BCIP-NBT)
with 4 M sodium chloride, pH 9.5.
The reaction was stopped by washing the strips in distilled water.
The strips showing protein recognition by the schistosomiasis patient
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sera were scanned using an optical densitometer and measured by analysis
of one-dimensional separation and dot blots using an Image Master
Program 1.20 produced by Pharmacia Biotech AB.
Statistical analysis: The results are expressed as mean and standard
deviation. The ANOVA test with the Student Newman-Keuls contrast
post-test was used for statistical analysis of the various groups. The paired
and unpaired Student test and Pearson correlation were used for statistical
comparison of two groups. A level of confidence of 95% (p < 0.05) was
considered as significant.
RESULTS
This study was carried out on 17 patients with a parasitological
diagnosis of schistosomiasis mansoni made by the Kato-Katz method.
Ninety days after treatment with oxamniquine (a single oral dose of 15
mg/kg weight) all patients yielded negative results in fecal exams; the
COPT, on the other hand, remained positive in one case (Table 1).
The immunoenzymatic tests (ELISA) performed with antigens
obtained from either adult worms (AWA) or S. mansoni  eggs (SEA) did
not show negative results up to 180 days after treatment. When AWA
was used an increase in antibody levels was observed 40 days after
treatment, followed by a significant decrease 140 days later, i.e. 180
days after treatment (Fig. 1). Anti-SEA IgG levels were significantly
decreased from 90 to 180 days after treatment (Fig. 2).
Table 1
Circumoval precipitin test (COPT) applied to 17 chronic schistosomiasis
patients before and after specific treatment
COPT
Patients Clinical Age Fecal eggs/g Before 180 days after
Form* (year) of feces  treatment # treatment #
1 I 34     96 + -
2 I 27   192 + -
3 I 39 2304 - -
4 I 32 1344 + -
5 I 29     24 + -
6 I 31     96 - -
7 I 32     24 + -
8 I 26   288 - -
9 HI 31   120 + -
10 HI 41     96 + -
11 I 42     24 - -
12 I 37     96 ND ND
13 I 21   432 + +
14 I 17 2472 + -
15 I 28   240 + -
16 I 26     24 - -
17 HI 77   672 + -
ND = not determined; * - Clinical form: hepatointestinal (HI) or intestinal (I); 
- Counting fecal egg excretion before oxamniquine treatment by the Kato-Katz
method21. The result is reported as the mean for three slides; # - Positive reaction
(+)  10% of immunoprecipitin around viable eggs.
Fig. 1 - Anti-AWA IgG antibodies detected by ELISA in 17 chronic schistosomiasis patients
before and after specific treatment. Cut off = 0.173. ANOVA test with p < 0.0001 followed
by the Student Newman-Keuls contrast post-test with *** p < 0.001, ** p < 0.01 and * p <
0.05 in relation to pre-treatment. Horizontal bar represents the mean value.
Fig. 2 - Anti-SEA IgG antibodies detected by ELISA in 17 chronic schistosomiasis patients
before and after specific treatment. Cut off = 0.208. ANOVA test with p < 0.0001 followed
by the Student Newman-Keuls contrast post-test with *** p < 0.001 in relation to pre-treatment.
Horizontal bar represents the mean value.
The anti-SEA IgG1, IgG2, IgG3 and IgG4 subclasses were determined
and significant decreases in IgG1, IgG3 and IgG4 levels but not in IgG2
were observed (Fig. 3). IgG4 showed  the most significant decrease 180
days after treatment, although the results were still positive.
A heterogenous pattern of reactivity was observed when the
immunoblotting for anti-AWA and SEA IgG antibodies of all 17 patients
were analyzed before and after 180 days after treatment (Tables 2 and
3). Table 4 shows the percentage of positive bands found in all patients
before and 180 days after treatment with oxamniquine.
DISCUSSION
In the present study, 17 schistosomiasis patients, 14 of them harboring
moderate or low parasite burdens, living for several years in a non-
endemic area for S. mansoni infection were examined before and after
treatment with oxamniquine. All of them had been considered cured by
fecal tests and all but one by COPT in the evaluation carried out six
months after treatment (Table 1). In contrast to reports by others14,31,33,
under our operational conditions COPT showed a relatively low
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Fig. 3 - Anti-SEA subclasses IgG1, IgG2, IgG3, IgG4 antibodies detected by ELISA in 17 chronic schistosomiasis patients before and after epecific treatment. Horizontal bar represents the mean
value. Cut off (IgG1 = 0.135, IgG2 = 0.175, IgG3 = 0.121, IgG4 = 0.152). Paired Student t test with *p < 0.01, **p < 0.05, ***p < 0.0001 in relation to pre-treatment.
Table 2
Antigenic bands reacting with IgG AWA found in chronic schistosomiasis patients
17 chronically schistosome-infected patients
KDa 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
204 ×× ×× ××
194 ×× ×¬ ×× ×× ×× ×× ×× ××
164 ×× ×× ×× ¬× ×× ×× ×× ×× ×× ×× ×× ××
152 ×× ×× ×× ×× ×× ×× ×× ××
130 ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
115 ×× ×× ×× ×× ×× ×× ×× ×× ××
92 ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
67 ×× ×× ×¬ ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
55 ×× ×× ×¬ ×¬ ×× ×× ×× ×¬ ×× ×× ×× ×¬ ×× ××
50 ×× ×× ×× ×× ×× ×× ×× ¬¬ ×× ×× ×× ×× ×× ××
40 ×× ×× ¬¬ ×× ×× ×¬
36 ×× ×× ¬¬ ×¬ ¬× ×× ×× ×× ×¬
31 ×× ×× ×× ×¬ ×× ×× ×× ×¬ ×× ×× ×¬ ×× ¬× ××
25 ×¬ ×× ×¬ ×× ×¬ ×× ×× ¬¬ ××
22 ×× ¬¬ ×× ××
The symbols in sequence correspond to the immunoblot reaction for each patient before and 180 days after specific treatment: (×)  reacting band and (¬)  non-reacting
band.
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Table 3
Antigenic bands reacting with IgG SEA found in chronic schistosomiasis patients
17 chronically schistosome-infected patients
KDa 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
203 ××
172 ×× ×× ×× ×× ×× ×× ×× ××
130 ×× ×¬ ×× ×¬ ×× ××
110 ×× ×× ×¬
92 ×¬ ×× ×× ×× ×× ×× ×× ××
73 ×¬ ×× ×× ×¬ ××
62 ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
55 ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
50 ×¬ ×× ×× ×× ×× ×× ×× ×× ×× ×× ××
41 ×× ×× ×× ×¬ ×¬ ×× ×× ×× ×× ×× ××
37 ×× ×× ×× ×¬ ×¬ ×× ×¬ ××
31 ×¬ ×× ×× ×¬ ×× ×× ×× ×¬ ××
25 ×× ×× ×¬ ×¬ ×× ×× ×¬ ××
22 ×× ×× ×× ×× ×¬ ×× ×× ×× ×× ×¬
18 ×× ×× ×× ×× ××
The symbols in sequence correspond to the immunoblot reaction for each patient before and 180 days after specific treatment: (×)  reacting band and (¬)  nonreacting
band.
Table 4
Percent (%) of anti-AWA IgG and anti-SEA IgG protein bands (kDa) in 17
chronically schistosome-infected patients before and after specific treatment
Anti-AWA Anti-SEA
% reactive patients % reactive patients
kDa before 180 days after before 180 days after
treatment treatment treatment treatment
204 18 18 06 06
194 47 41 47 47
164 71 71 35 23
152 47 47 18 12
130 71 71 47 41
115 53 53 29 18
92 88 88 76 76
67 82 76 71 71
55 82 59 65 59
50 82 76 65 53
40 35 23 47 29
36 53 35 53 35
31 82 65 47 29
25 53 29 59 47
22 23 18 29 29
Forty-days after treatment with oxamniquine anti-AWA IgG-ELISA,
but not anti-SEA IgG-ELISA antibodies showed a significant increase
(Fig. 1) probably as a consequence of antigen release following worm
death34,39. Up to six months after oxamniquine treatment both anti-AWA
and anti-SEA IgG antibody levels showed a significant decrease (Fig. 1
and 2), although not reaching the level of non-infected controls.
As also observed by others, the levels of IgG1, IgG2, IgG3 and
principally IgG4 anti-SEA antibodies were significantly higher than those
found in non-infected people before oxamniquine treatment2,18,19 (Fig.
3). Six months after oxamniquine administration a sharp decrease in
IgG4 levels and a less significant decrease in IgG1 and IgG3 levels were
observed. These results are in agreement with the  assumption of best
performance of schistosome egg antigens in the evaluation of specific
schistosomiasis treatment, as already pointed out by other
investigators6,30,42.
Positive anti-schistosome serological reactions in patients submitted
to efficient specific treatment could be explained either by the persistence
of some living worms, without oviposition, in the host’s portal system44
or by the temporary persistence of schistosome antigens in host tissues12,41.
In the 17 patients studied here both anti-AWA and anti-SEA antibody
tests resulted positive at least up to six months after oxamniquine
administration, indicating that these immunological tests cannot be used
for treatment evaluation. However, the  greatest decrease in IgG4 levels
verified six months after treatment (Fig. 3) deserves attention. This
immunoglobulin subclass has been considered as a relatively good marker
for worm burden2 and, on the other hand, it has been identified as the
first antibody subclass to decrease after anti-S. mansoni and anti-S.
haematobium treatment11,33. According to our results, although showing
positive levels six months after oxamniquine administration, the
determination of IgG4 anti-SEA antibodies could be used as a preliminary
test for treatment evaluation in schistosomiasis patients.
sensitivity before treatment. Of 16 patients submitted to this diagnostic
procedure only 11 (68.7%) yielded positive results.
The results of immunological tests (anti-AWA and anti-SEA IgG-
ELISA) performed before specific treatment were similar to those
obtained by others13,26,28,40 and support the usefulness of these techniques
for schistosomiasis diagnosis, mainly in areas where the parasite burden
is low and consequently fecal tests are less sensitive20.
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Analysis of IgG anti-AWA and anti-SEA immunoblottings showed
a heterogeneous pattern before and after specific treatment in the 17
patients studied. The bands of 31-32 kDa, considered to be of high
diagnostic value17,35,36,37, were found in 82% and 53% of cases,
respectively, before treatment when AWA and SEA were analyzed (Tables
2 and 3). This kind of diversity was, in fact, previously pointed out by
others in Brazilian schistosomiasis patients: VALLI et al.43 found 98%
positivity for the 31 kDa band and KIMURA22 found only 12.5%
positivity for the same strand.
Although the 31-32 kDa bands have been considered as good markers
for schistosomiasis cure after specific treatment by some researchers23,38,
in the evaluation performed 180 days after oxamniquine administration
these bands vanished in only three cases (Tables 2 and 3), persisting in
65% and 29% of the patients studied when AWA and SEA antigens
were used, respectively (Table 4).
In summary, the use of COPT, immunoenzymatic tests as well as the
immunoblotting techniques did not permit a safe and definitive early
evaluation of schistosomiasis treatment in the 17 patients studied. Thus, the
ideal diagnostic method for schistosomiasis cure control seems to be still far
from available, but IgG4 subclass levels showed a significant decrease up to
180 days after specific treatment. Long term post treatment follow-up would
be relevant and other studies are necessary to define in further detail the role
of IgG4 and its promising usefulness as a possible cure marker.
RESUMO
Avaliação da presença de anticorpos IgG anti-Schistosoma
mansoni no soro de pacientes com esquistossomose mansônica
crônica, antes e após tratamento específico
Em 17 pacientes com infecção crônica por Schistosoma mansoni
utilizaram-se os testes de reação periovular, imunoenzimático (ELISA) e
imunoblotting, empregando-se antígenos obtidos a partir de vermes adultos
(AWA) ou de ovos de S. mansoni (SEA), para detecção de anticorpos anti-
S. mansoni, antes e em quatro ocasiões após tratamento com oxamniquine.
Quando cotejados a grupo controle os pacientes esquistossomóticos
revelaram altos níveis séricos de anticorpos IgG nos testes ELISA (anti-
AWA e anti-SEA), não se observando, porém, negativação até seis meses
após tratamento específico. Encontrou-se, entretanto, decréscimo
significativo, sem negativação, dos níveis de IgG1, IgG3 e, principalmente,
IgG4, quando se utilizou antígeno solúvel obtido a partir de ovos de S.
mansoni (SEA), seis meses após administração de oxamniquine. O mesmo
não foi observado no caso de anticorpos da subclasse IgG2.
Nos imunoblottings efetuados com o emprego de antígeno de verme
adulto (AWA), antes do tratamento com oxamniquine, evidenciou-se a
presença de banda com 31 kDa em 14 (82%) dos 17 pacientes estudados,
observando-se seu desaparecimento em três pacientes examinados seis
meses após tratamento específico. Quando se utilizou antígeno obtido a
partir de ovos de S. mansoni (SEA) a mesma banda foi evidenciada em
nove pacientes, desaparecendo em quatro casos, após o tratamento.
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